Librela for Dogs: The Monthly Arthritis Injection Revolutionizing Pain Relief

Last updated: May 6, 2026

If your dog has been slowing down on walks, struggling to get up from the floor, or hesitating before jumping onto the couch, osteoarthritis may be the reason. For decades, veterinarians had a limited toolkit for managing this condition — mostly nonsteroidal anti-inflammatory drugs and the careful hope that they would not damage a dog’s internal organs over time. That changed with the arrival of Librela for dogs, a once-monthly injection that takes an entirely different approach to arthritis pain relief and has quickly become one of the most talked-about treatments in veterinary medicine.

What Is Librela (Bedinvetmab)?

Librela is the brand name for bedinvetmab, a monoclonal antibody specifically designed to manage pain associated with osteoarthritis in dogs. Unlike traditional pain medications that work broadly across the body’s inflammatory or pain pathways, Librela is a biologic therapy — a treatment derived from living cells that is engineered to target one very specific molecule in the body.

Developed by Zoetis, the same company behind many widely used veterinary products, Librela represents a fundamentally new category of pain relief for dogs. It is not an NSAID, not a steroid, and not a gabapentin-style nerve pain medication. It is a purpose-built antibody that locks onto a single protein responsible for transmitting pain signals in arthritic joints.

The active ingredient, bedinvetmab, is a caninized monoclonal antibody, meaning it has been engineered to closely resemble a dog’s own natural antibodies. This is important because it reduces the likelihood that a dog’s immune system will recognize the drug as foreign and mount a reaction against it. The result is a treatment that can be given repeatedly over months or years with a favorable safety profile.

How Librela Works: The Anti-NGF Approach

To understand why Librela for dogs is considered such a significant advance, it helps to understand the molecule it targets: nerve growth factor, or NGF.

NGF is a protein that plays a central role in pain signaling. In healthy joints, NGF levels are relatively low. But in joints affected by osteoarthritis, NGF production increases dramatically. This elevated NGF sensitizes the nerve endings in and around the joint, amplifying pain signals and making even normal movement uncomfortable. It is one of the key reasons why arthritis pain tends to worsen over time — as joint damage progresses, NGF levels climb, and the nervous system becomes increasingly tuned to report pain.

Librela works by binding to NGF before it can attach to nerve receptors. Once bedinvetmab locks onto an NGF molecule, that molecule is effectively neutralized — it can no longer activate pain pathways. The result is a meaningful reduction in the pain signals reaching the brain, which translates to improved comfort, better mobility, and a more normal quality of life for the dog.

This anti-NGF mechanism is the same principle behind Solensia (frunevetmab), the companion product made for cats with osteoarthritis. Both drugs target nerve growth factor, but each is engineered specifically for its respective species. If you have a cat with arthritis and are already familiar with how Solensia works, the concept behind Librela will feel very familiar.

Critically, because Librela does not work through the cyclooxygenase (COX) enzyme pathway that NSAIDs rely on, it avoids the gastrointestinal, kidney, and liver risks that have long been the primary concern with traditional arthritis medications in dogs.

FDA Approval and Regulatory Status

Librela received FDA approval in the United States in May 2023 for the control of pain associated with osteoarthritis in dogs. It had already been approved and in widespread use across Europe, the United Kingdom, and other international markets before reaching the US, which means there is a substantial body of real-world clinical experience supporting its safety and effectiveness.

The FDA approval was based on clinical trials demonstrating that dogs receiving Librela showed statistically significant improvements in pain scores compared to dogs receiving a placebo. Veterinarians and dog owners reported noticeable changes in mobility, willingness to exercise, and overall demeanor in treated dogs — the kinds of improvements that matter most in daily life.

Which Dogs Is Librela For?

Librela is approved for dogs diagnosed with osteoarthritis pain. In practical terms, this covers a very large population. Osteoarthritis is one of the most common chronic conditions in dogs, affecting an estimated one in four dogs over the age of one, with prevalence increasing sharply in middle-aged and senior dogs.

Your veterinarian may recommend Librela if your dog shows signs of joint pain such as stiffness after rest, reluctance to climb stairs or jump, decreased interest in walks or play, limping or favoring a limb, or difficulty lying down and getting up. A diagnosis typically involves a physical examination and may include radiographs to confirm joint changes.

Librela is suitable for dogs of all sizes, from small breeds to giant breeds. It is dosed by body weight, so the veterinarian selects the appropriate concentration and volume for each individual dog. It is approved for dogs at least twelve months of age. If you are considering adopting a senior dog and want to understand how to support their joint health, our adoption page can help you find dogs who are looking for a comfortable home.

The Monthly Injection: What to Expect at the Vet

One of the practical advantages of Librela is its simple administration schedule. It is given as a single subcutaneous injection — just under the skin — once every month at your veterinarian’s office. The injection itself takes only a few seconds, and most dogs tolerate it well with minimal discomfort, similar to a routine vaccination.

You cannot administer Librela at home. It must be given by a veterinary professional, which means a monthly visit. While this is less convenient than giving a daily pill at home, many veterinarians and dog owners consider it an advantage rather than a drawback. It eliminates the daily struggle of pilling a reluctant dog, removes the risk of missed doses, and ensures your dog is seen by a veterinarian regularly — providing an opportunity to monitor the arthritis progression and overall health at each visit.

The injection is given in the area between the shoulder blades or along the back. No fasting or special preparation is needed beforehand, and dogs can return to their normal routine immediately afterward.

How Fast Does Librela Work?

Many dog owners report seeing improvements within the first week after the initial injection. In clinical studies, measurable reductions in pain scores were observed as early as seven days after treatment, with continued improvement over the following weeks.

However, the response can vary. Some dogs show dramatic improvement after their very first injection — getting up more easily, walking farther, playing again. Others may need two or three monthly injections before the full benefit becomes apparent. Veterinarians generally recommend committing to at least three consecutive monthly doses before evaluating whether Librela is working effectively for a particular dog.

The effect of each injection lasts approximately one month, which is why the treatment is given on a regular monthly schedule. If a dose is significantly delayed, the dog may experience a return of pain symptoms before the next injection.

Side Effects of Librela in Dogs

Librela has a generally favorable side effect profile, which is one of the main reasons it has gained rapid adoption. In clinical trials and post-market surveillance, the most commonly reported side effects include:

• Injection site reactions: Mild swelling, redness, or tenderness at the injection site, typically resolving within a day or two
• Urinary tract infections: Reported at a slightly higher rate in treated dogs compared to placebo groups in some studies
• Bacterial skin infections: Occasional reports of dermatitis or skin infections
• Vomiting and diarrhea: Mild gastrointestinal signs reported infrequently
• Lethargy: Temporary decreased energy in some dogs following injection

Serious adverse events are rare. As with any biologic therapy, there is a theoretical risk of an immune-mediated reaction, but reports of anaphylaxis or severe hypersensitivity with Librela have been extremely uncommon. Your veterinarian will discuss the specific risk profile as it relates to your dog’s individual health history.

Librela should not be used in breeding, pregnant, or lactating dogs, as safety has not been evaluated in these populations. It is also not indicated for dogs under twelve months of age.

How Much Does Librela Cost?

The cost of Librela varies depending on your location, veterinary clinic, and your dog’s size (since larger dogs require a higher dose). As a general range, most dog owners can expect to pay between $65 and $250 per monthly injection. Smaller dogs tend to fall at the lower end of this range, while large and giant breeds may be at the higher end.

When evaluating cost, it is worth considering the total picture. A dog on daily NSAIDs also incurs costs for the medication itself plus the recommended blood work every six to twelve months to monitor liver and kidney function. With Librela, the need for routine blood monitoring specifically related to the pain medication is reduced, though your veterinarian may still recommend periodic wellness testing appropriate for your dog’s age and health status.

Some pet insurance plans cover Librela as a treatment for diagnosed osteoarthritis. If your dog has pet insurance, check with your provider about coverage before starting treatment.

Librela vs. NSAIDs vs. Galliprant: How They Compare

Choosing the right arthritis medication for your dog is a conversation best had with your veterinarian, but understanding the basic differences between the main options can help you ask informed questions.

Traditional NSAIDs (carprofen, meloxicam, deracoxib): These have been the standard of care for canine osteoarthritis for years. They work by inhibiting COX enzymes involved in inflammation and pain. They are effective, relatively affordable, and available as daily oral medications. The trade-off is that long-term NSAID use carries risks to the gastrointestinal tract, kidneys, and liver, requiring regular blood work to monitor organ function. Dogs with pre-existing kidney or liver disease may not be candidates for NSAID therapy.

Galliprant (grapiprant): Galliprant is a newer oral medication that targets a specific prostaglandin receptor (EP4) rather than broadly inhibiting COX enzymes. This more targeted approach is associated with a somewhat better gastrointestinal safety profile than traditional NSAIDs, though kidney and liver monitoring is still recommended. Galliprant is given daily as a tablet and has become popular as a first-line option for dogs with mild to moderate arthritis pain.

Librela (bedinvetmab): Librela works through an entirely different mechanism — anti-NGF — that does not involve the COX pathway or prostaglandin receptors at all. This makes it a particularly attractive option for dogs who have experienced side effects from NSAIDs, dogs with compromised kidney or liver function, and dogs whose owners prefer to avoid daily oral medication. The monthly injection schedule is convenient for compliance but does require regular veterinary visits.

In some cases, veterinarians may recommend combining Librela with other therapies — including low-dose NSAIDs, physical rehabilitation, weight management, or joint supplements — for a multimodal approach to pain management. Always follow your veterinarian’s guidance on combining medications.

Long-Term Safety of Librela

Because Librela is a relatively new product in the US market, long-term safety data is still accumulating. However, the available evidence is encouraging. Dogs in extended clinical trials received monthly injections for up to nine months with no significant increase in adverse events over time. European markets have had access to the product for a longer period, and post-market surveillance data continues to support a favorable safety profile.

One of the most frequently asked questions about long-term use concerns whether blocking NGF could have unintended consequences beyond pain relief. NGF does play roles in nerve maintenance and repair, so the question is a reasonable one. To date, clinical evidence has not shown significant neurological complications from sustained anti-NGF therapy in dogs at the approved dose. Nonetheless, ongoing monitoring and continued research are important, and your veterinarian will stay current on the latest safety information.

Dogs on Librela long-term should continue to receive regular veterinary wellness examinations, not specifically because of the drug, but because any dog with a chronic condition like osteoarthritis benefits from ongoing professional oversight.

Kidney and Liver Safety: A Major Advantage

For many dog owners and veterinarians, the most compelling aspect of Librela for dogs is what it does not do: it does not rely on pathways that stress the kidneys or liver.

NSAIDs are metabolized through the liver and excreted through the kidneys, which is why long-term use can contribute to organ damage — particularly in older dogs whose kidney and liver function may already be declining. This creates a difficult situation: the dogs who need arthritis pain relief the most (older dogs) are often the same dogs who are least able to tolerate the medications traditionally used to provide it.

Librela, as a monoclonal antibody, is broken down through normal protein catabolism — the same process the body uses to recycle its own antibodies. It does not pass through the liver for metabolism or the kidneys for excretion in the way that small-molecule drugs do. This means it can be used in dogs with compromised renal or hepatic function, a population that has historically had very limited options for effective pain control.

This does not mean that dogs on Librela never need blood work. Age-appropriate wellness screening is still important. But the specific concern about drug-induced organ damage that accompanies long-term NSAID use is largely absent with Librela.

Monitoring Your Dog on Librela

Even though Librela has a favorable safety profile, responsible use includes ongoing monitoring. Here is what that looks like in practice:

• Monthly veterinary visits: Since Librela must be administered at the vet’s office, your dog will be seen professionally every month. This is an opportunity for a brief physical assessment and for you to report any changes you have observed at home.
• Pain and mobility tracking: Keep notes on your dog’s comfort level, activity, and behavior between visits. Many veterinarians use validated pain scoring tools and appreciate owner input when assessing treatment effectiveness.
• Annual or biannual wellness blood work: Recommended for all senior dogs regardless of what medications they are taking. This catches age-related changes in organ function, blood cell counts, and metabolic markers early.
• Weight management: Maintaining a healthy weight is one of the single most important things you can do for a dog with arthritis. Excess weight increases joint stress and accelerates cartilage breakdown. Your veterinarian can help you set a target weight and adjust diet accordingly.
• Watch for new symptoms: Report any unusual signs to your veterinarian promptly, including changes in appetite, urination patterns, skin condition, energy level, or behavior. Early detection of any issue — whether related to the medication or not — leads to better outcomes.

Dog Breeds That Benefit Most from Librela

While any dog with osteoarthritis can potentially benefit from Librela, certain breeds are disproportionately affected by joint disease and may be especially strong candidates for this treatment. Large and giant breeds are particularly prone to osteoarthritis due to the greater mechanical stress on their joints. Breeds with known predispositions include:

• Labrador Retrievers: One of the breeds most commonly affected by hip and elbow dysplasia, which frequently progresses to osteoarthritis
• Golden Retrievers: High prevalence of hip dysplasia and cruciate ligament disease, both leading contributors to arthritis
• German Shepherds: Prone to degenerative joint disease, particularly in the hips and spine
• Rottweilers: Susceptible to both hip and elbow dysplasia at significant rates
• Great Danes: Giant breed status means substantial joint loading and early-onset arthritis in many individuals
• Bernese Mountain Dogs: High rates of elbow dysplasia and associated osteoarthritis
• Bulldogs and French Bulldogs: Spinal and joint issues related to their body conformation
• Dachshunds: While small, their elongated body structure predisposes them to spinal arthritis and intervertebral disc disease
• Corgis: Similar to dachshunds, their long-backed conformation contributes to spinal and joint stress

That said, mixed-breed dogs develop osteoarthritis at high rates too, and any dog that has experienced joint injury, cruciate ligament surgery, or carries excess weight is a potential candidate regardless of breed. You can learn more about breed-specific health considerations in our dog breeds directory.

Frequently Asked Questions

Is Librela a cure for arthritis in dogs?

No. Librela manages the pain associated with osteoarthritis, but it does not reverse joint damage or cure the underlying disease. Osteoarthritis is a progressive condition, and Librela is best understood as a tool for maintaining comfort and quality of life while the disease is managed through a broader plan that may include weight control, exercise modification, physical therapy, and joint supplements.

Can Librela be used alongside other medications?

In many cases, yes. Veterinarians sometimes use Librela as part of a multimodal pain management plan that may include low-dose NSAIDs, gabapentin, adequan injections, or joint supplements. However, any combination of medications should be directed by your veterinarian, who can assess the risks and benefits for your specific dog.

What happens if I stop giving my dog Librela?

If you discontinue Librela, the pain-relieving effect will gradually wear off as the antibody is naturally cleared from your dog’s system. Most dogs will begin to show a return of arthritis symptoms within four to six weeks after the last injection. There is no withdrawal effect or rebound pain phenomenon — the dog simply returns to their pre-treatment baseline over time.

How do I know if Librela is working for my dog?

Look for improvements in daily function: getting up more easily, walking farther or more willingly, climbing stairs with less hesitation, playing more, sleeping more comfortably, and generally seeming brighter and more engaged. Many owners also notice that their dog’s temperament improves — dogs in chronic pain can become irritable or withdrawn, and effective pain relief often brings a return of their normal personality.

Is Librela safe for dogs with kidney disease?

Librela is considered a favorable option for dogs with kidney disease because it is not metabolized through the kidneys the way NSAIDs are. This makes it one of the few effective pain management options for dogs whose renal function has declined. Your veterinarian can evaluate whether Librela is appropriate for your dog’s specific situation.

Can puppies or young dogs receive Librela?

Librela is approved for dogs twelve months of age and older. It is not indicated for puppies or dogs under one year. Most dogs who need osteoarthritis treatment are middle-aged or older, though younger dogs with joint injuries or developmental orthopedic conditions may also be candidates once they meet the age requirement.

Does my dog need a diagnosis before starting Librela?

Yes. Librela is a prescription medication that requires a veterinary diagnosis of osteoarthritis. Your veterinarian will perform a physical examination and may take radiographs or recommend other diagnostics to confirm that osteoarthritis is the cause of your dog’s pain before prescribing treatment. If you think your dog may be showing signs of joint pain, the first step is scheduling a veterinary appointment for evaluation.